Effect of SARS-CoV-2 vaccination in a vulnerable COVID-19 cohort: a real-life experience in an Italian Hospital-Reference-Cited by-同舟云学术

Effect of SARS-CoV-2 vaccination in a vulnerable COVID-19 cohort: a real-life experience in an Italian Hospital

Published:2023-08-23 Issue:8 Volume:35 Page:730-736
ISSN:1120-009X
Container-title:Journal of Chemotherapy
language:en
Short-container-title:Journal of Chemotherapy

Author:

Russo Chiara¹²,Tagliafico Luca³,Labate Laura¹²,Ponzano Marta⁴,Mirabella Michele²,Portunato Federica²,Bellezza Carmen⁵,Mora Sara⁶,Arboscello Eleonora⁵,Monacelli Fiammetta²³,Nencioni Alessio²³,Signori Alessio⁴,Bruzzone Bianca⁷,Giacomini Mauro⁶,Dentone Chiara²,Bassetti Matteo¹²

Affiliation:

1. Division of Infectious Diseases, Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy

2. IRCCS Ospedale Policlinico San Martino, Genoa, Italy

3. Department of Internal Medicine (DIMI), Geriatric Clinic, University of Genoa, Genoa, Italy

4. Section of Biostatistics, Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy

5. Department of Emergency, IRCCS Ospedale Policlinico San Martino, Genoa, Italy

6. Department of Informatics Bioengineering, Robotics, and Systems Engineering (DIBRIS), University of Genova, Genoa, Italy

7. Hygiene Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy

Publisher

Informa UK Limited

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/1120009X.2023.2246716

Reference24 articles.

1. COVID-19 pandemic: from origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and management;Ochani R;Infez Med,2021

2. BNT162b2 mRNA COVID-19 Vaccine: First Approval

3. Immunogenicity and Safety of the COVID-19 Vaccines Compared With Control in Healthy Adults: A Qualitative and Systematic Review

4. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

5. SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3